Synergistic bacterial compositions and methods of production and use thereof
Inventors
Henn, Matthew R. • von Maltzahn, Geoffrey • D'Onofrio, Anthony Mario • Litcofsky, Kevin Daniel • Berry, David A. • Cook, David N. • Afeyan, Noubar B. • Aunins, John Grant
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
Core Innovation
The disclosed invention is a therapeutic composition comprising two purified bacterial populations: a first population defined by 16S rDNA sequence identity to a reference Collinsella aerofaciens OTU, and a second defined by sequence identity to a reference bacterium of the family Clostridiaceae listed in Table 1. Their synergistic combination is cytotoxic or cytostatic to a pathogenic bacterium, particularly a pathogenic Clostridium difficile bacterium.
The supplied summary describes the bacterial combinations as intended to functionally populate the gastrointestinal tract and prevent or treat dysbiosis and infection. The background section is not included in the supplied content, so the specific problem identified in that section is not explicitly described in patent. A screening result reports inhibition for binary and ternary combinations, but the partial content does not provide further background on the problem being addressed.
Claims Coverage
The supplied claims identify one independent claim. It covers a therapeutic composition containing two purified bacterial populations defined by 16S rDNA sequence identity, with a synergistic combination that is cytotoxic or cytostatic to a pathogenic bacterium; dependent claims add target, effect, and composition refinements.
Two purified bacterial populations
The composition comprises a first purified bacterial population with 16S rDNA sequence at least about 97% identical to a sequence present in a reference Collinsella aerofaciens OTU, and a second purified bacterial population with 16S rDNA sequence at least about 97% identical to a sequence present in a reference bacterium of the family Clostridiaceae listed in Table 1.
Synergistic effect on a pathogenic bacterium
The synergistic combination of the first type and the second type is cytotoxic or cytostatic to a pathogenic bacterium. A dependent claim identifies pathogenic Clostridium difficile as a target.
Functional populating of the gastrointestinal tract
A dependent claim describes functional populating of the gastrointestinal tract that reduces pathogenic bacteria or increases non-pathogenic bacteria.
Optional anti-infective agent
A dependent claim provides that the composition further comprises an effective amount of an anti-bacterial, anti-fungal, anti-viral, or anti-parasitic agent.
The claim coverage centers on a therapeutic composition with two sequence-defined purified bacterial populations whose synergistic combination acts against a pathogenic bacterium. Dependent claims specify Clostridium difficile, gastrointestinal populating effects, and optional anti-infective agents.
Stated Advantages
The synergistic combination is cytotoxic or cytostatic to a pathogenic bacterium; a dependent claim specifies pathogenic Clostridium difficile.
Functional populating of the gastrointestinal tract reduces pathogenic bacteria or increases non-pathogenic bacteria.
Documented Applications
A therapeutic bacterial composition intended to prevent or treat dysbiosis and infection, including infection involving Clostridium difficile.
Functional populating of the gastrointestinal tract to reduce pathogenic bacteria or increase non-pathogenic bacteria.
Interested in licensing this patent?